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hospitalar e custo do procedimento. Métodos: A partir do sistema de faturamento 
do HIAE foram selecionados 538 procedimentos de septoplastia com turbinecto-
mia e sinusectomia realizados no ano de 2011 que utilizaram as técnicas com-
paradas neste estudo. Foram incluídos na análise 517 pacientes, 56 procedimentos 
utilizando o microdebridador e 461 utilizando a técnica convencional. Em média, 
os pacientes que utilizaram o microdebridador possuíam uma faixa etária mais 
elevada e um percentual maior dos pacientes apresentaram diagnóstico de sinusite 
crônica. ResultAdos: Em relação à média de tempo de permanência hospitalar 
esta foi maior no grupo do microdebridador (28 horas versus 22 horas no grupo 
da técnica convencional, p= 0,002). A quantidade média de unidades de cola e de 
hemostático foi maior no grupo que utilizou o microdebridador. Não houve difer-
ença estatística entre os grupos nos desfechos de tempo de cirurgia e nas taxas de 
readmissão hospitalar. No desfecho de dor no pós operatório imediato a diferença 
entre os grupos foi estatisticamente significativa (p = 0,006), indicando um per-
centual maior de pacientes com escore de dor acima de 5 sendo tratados com o 
microdebridador, quando comparado com o grupo convencional. Considerando-se 
o custo do procedimento com a técnica convencional como referência, o uso do 
microdebridador resultou em um aumento médio de 17,4% em relação à técnica 
convencional. ConClusões: O uso do microdebridador não se mostrou favorável 
nos desfechos avaliados, tendo em vista um aumento do tempo de permanência do 
paciente, uso de colas e hemostáticos em maior quantidade que a técnica conven-
cional e o custo do procedimento foi significativamente mais alto.
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objeCtives: Economic burden in Chronic Obstructive Pulmonary Disease (COPD) 
patients with varying levels of dyspnoea is largely unknown. The objective of this 
retrospective analysis was to estimate the resource use and the associated costs 
incurred by COPD patients with increasing levels of dyspnoea with or without fre-
quent exacerbations. Methods: A retrospective cohort of prevalent COPD patients 
was identified in the Clinical Practice Research Datalink (CPRD). All patients who had 
at least 12 month pre- and post- cohort entry date (1st prevalent COPD diagnosis 
confirmed by spirometry ≥ April 1, 2009) recorded were included in the analysis. 
Patients were categorised as having none, 1 or 2+ exacerbations in the 12 months 
post cohort entry and further classified using Medical Research Council (MRC) dysp-
noea scale. Study outcomes included general practitioner (GP) visits, community 
treated exacerbations (medical dg for exacerbation or ATB+OCS Rx), hospital treated 
exacerbations and all-cause hospitalisations excluding COPD exacerbations. The 
costs associated with the estimated resource use were calculated using National 
Health Service (NHS) reference costs for 2010-11. Results: The cohort consisted 
of 51,641 COPD patients with 27,764 (53.8%), 12,585 (24.4%) and 11,292 (21.9%) hav-
ing experienced none, 1 and 2+ annual exacerbations post cohort entry. Among all 
patients, the estimated annual COPD management costs, excluding the costs of 
medications, were £1,597, £1,849, £2,298, £2,745 and £3,579 with increasing levels 
of dyspnoea (MRC grade 1-5). The equivalent cost ranges by exacerbation frequency 
were £1,267-£2,235, £2,021-£3,447 and £2,627-£4,709 for patients with none, 1 or 2+ 
annual exacerbations, respectively. ConClusions: Increase in COPD management 
costs with increase in level of dyspnoea occurred in all exacerbation frequency 
groups. Better symptom control and disease management strategies in primary 
care setting may help reduce COPD costs significantly.
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objeCtives: Smoking is the single most preventable cause of disease and death all 
around the world. Our objective was to quantify the disease burden associated with 
smoking in Argentina, Bolivia, Brazil, Chile, Colombia, Mexico and Peru. Methods: 
The project began with a survey to health Decision Makers (DM) to explore country-
specific information needs. The development stage involved the harmonization of 
a methodology to retrieve local relevant parameters and develop the model struc-
ture. A microsimulation HEM was built considering the availability and quality of 
epidemiological data and relevant outcomes were conceived to suit the identified 
information needs of DMs . It considers all tobacco-related diseases: heart, cerebro-
vascular and chronic obstructive pulmonary disease, pneumonia/influenza, lung 
cancer and nine other neoplasms. A systematic search on effectiveness, local epide-
miology and costs studies was undertaken to populate the model. Calibration and 
validation was performed for each country. Predicted event rates were compared 
to the published rates used as model inputs. External validation was undertaken 
against epidemiological studies not used to provide input data. Results: The cali-
brated model showed all simulated event rates falling within ±10% of the sources 
and a high correlation between published data and model results. In these seven LA 
countries, tobacco is responsible of 259,126 deaths each year. The diseases attrib-
utable to smoking cause a total of 1∙90 million years of life lost due to premature 
death, 0∙64 million years of life lost due to disability and at least 27 billion dollars 
(USD dollars 2013) in direct medical costs each year. ConClusions: Tobacco use is 
real world treatment patterns in Insomnia patients and majority of these stud-
ies focused on benzodiazepine users. The rate of medication use in Insomnia 
patients is fairly low and rates were ranging from 17% to 75%. There were a total 
of 11 trials published testing Eszopiclone use, 10 trials each on Ramelteon and 
Zolpidem, 4 trials on Indiplon, 3 trials on Gaboxadol, 3 trials on Doxepin use in 
patients diagnosed with Insomnia. Several patient reported outcomes measures 
were used in the assessment of various clinical trials. ConClusions: There 
were a variety of agents being used to treat insomnia; while benzodiazepines 
and non-benzodiazepines were largely popular. Products in development need to 
be studied further to determine whether their new mechanisms of action were 
truly beneficial for treatment.
RESPiRatoRy-RELatEd diSoRdERS – Clinical outcomes Studies
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objeCtives: To investigate the patient’s acute asthma characteristics, and iden-
tify predictors of asthma control in a population of asthma patients from five 
Latin American countries. Methods: Adults and parents of adolescents (12-17 
years) with a physician diagnosed asthma and asthma medication use or asthma 
attacks in the past year were surveyed as part of the 2011 Latin America Asthma 
Insights and Management (AIM) survey. Using Global Initiative for Asthma (GINA) 
guidelines as a reference, respondents were categorized into three levels of asthma 
control: well-controlled, partly- controlled, and uncontrolled. Chi-square tests 
and adjusted logistic regression were used to determine odds ratios (ORs) to 
assess the relation of degree of asthma control with frequency of sudden asthma 
episodes, frequency of asthma symptoms, duration of episodes, day-and night 
time symptoms, utilization of rescue medications, and asthma episodes season-
ality. Results: Data from 2168 adults and parents from asthma patients ≥ 12 
years survey was analyzed. Seven percent (7%) of the patients are controlled, 57% 
partially controlled, and 36% uncontrolled. Adjusted logistic regression models 
showed that patients whose asthma was uncontrolled were significantly more 
likely to have acute sudden asthma episodes compared to patients whose asthma 
was controlled either partially or fully. Similarly, patients with uncontrolled 
asthma were significantly more likely to have higher frequency of asthma episodes 
in most days of the week, increased day and night symptoms than those asthmat-
ics who were controlled ConClusions: Patients who did not have well-controlled 
asthma had more acute episodes as compared to patients whose asthma was 
well-controlled. Our results strongly suggest that the acute asthma requires a 
significant effort to decrease its severity.
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objeCtives: Graphic health warnings (GHWs) on cigarette packages have been 
found to be significantly associated with increased awareness of smoking-related 
health hazards as well as behavior change. Legislations on GHWs have recently 
been endorsed and GHWs have now been introduced in Qatar. This study aims to 
evaluate the general public’s awareness, beliefs and perceptions on anti-tobacco 
GHW labels on cigarette packs prior to the introduction of the new law. Methods: 
A cross-sectional survey using a pretested 23-item questionnaire was conducted 
among randomly approached adults in Qatar. Data were analyzed using the IBM 
SPSS® version 19. Responses were analyzed by smoking status (ever-smokers 
vs. never-smokers) to ascertain how these two distinct groups differed in their 
awareness and perceptions related to health warning messages. The demographic 
characteristics and other outcomes of interest were compared using χ 2 or Fishers 
Exact tests. Results: A total of 500 participants (59% male) responded to the sur-
vey. Most notably, ever-smokers did not significantly differ from never-smokers 
on awareness of GHW. About one-third of the respondents had no idea about any 
specific text warning messages on tobacco products sold and nearly 45% of them 
did not know what a GHW was. Furthermore, a substantial proportion (more than 
20%) of the respondents in both groups did not believe that introducing GHWs 
will enhance smoking behavior change. Non-smokers generally tended to have 
more positive attitudes than smokers toward the perceived impact of GHWs (p < 
0.05). ConClusions: A substantial proportion of the general public in Qatar had 
poor awareness about GHWs. This study has important implications on the needs 
to increase awareness about the value of GHWs as well as calls for further research 
to determine the effectiveness of GHW labels on cigarette packages in Qatar and 
the greater Middle Eastern region, where legislations on GHWs are still at infancy.
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objetivos: O objetivo deste estudo foi comparar as técnicas cirúrgicas com uso 
do microdebridador em relação à técnica convencional nos procedimentos de sep-
toplastia com turbinectomia e sinusectomia, quanto ao tempo de cirurgia, tempo 
de hospitalização, uso de colas e hemostáticos, escore de dor, taxa de readmissão 
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objeCtives: Little information exists on the acute treatment provided for rhi-
nosinusitis and its associated costs. We hypothesize that introducing the admin-
istration of mometasone furoate (MFNS) as a treatment for rhinosinusitis will 
have a substantial impact on medical resource costs, outcomes and possibly 
cost-effectiveness. The goal of this paper is to estimate the cost-effectiveness of 
treating patients with rhinosinusitis with MFNS versus amoxicillin. Methods: A 
decision-analytic model was developed to estimate lifetime costs and outcomes 
associated with MFNS 200µg twice daily and amoxicillin 500mg three times daily 
in treating rhinosinusitis from the Mexican health care perspective. This study 
further do not included MFNS 200µg once daily as a treatment arm because it 
was not found to be superior to amoxicillin. Data sources included published 
literature, clinical trials, official price/tariff lists, and Delphi panel data. The time 
horizon was 2 weeks. The effectiveness outcomes of the study were modeled 
as changes in the Major Symptom Score (MSS). MSS consists of five questions 
concerning rhinorrhoea, post-nasal drip, nasal congestion, sinus headache, and 
facial pain. Costs were valued in US dollar, year 2012 values. Multiple 1-way 
sensitivity analyses and a probabilistic sensitivity analysis using Monte Carlo 
simulation were performed to handle uncertainty. Results: The projected costs 
were US$ 258 with MFNS and $US 272 with. The benefits (changes in the MSS) were 
0.52 with MFNS 0.45 with Amoxicilin. MFNS was associated with a cost savings 
per patient of US$ 14 versus amoxicillin over a period of 2 weeks from a health 
care perspective. The incremental cost-effectiveness ratio for MFNS dominated 
Amoxicilin. Sensitivity analysis confirmed the overall cost savings and gains 
in effectiveness. ConClusions: Our analysis suggests MFNS improves health 
outcomes in a cost-effective manner compared with Amoxicilin. The economic 
value of Amoxicillin is influenced by difficulties involved in diagnosing the condi-
tion, effectiveness, resistance, patient compliance with treatment, and treatment 
failure associated with antibiotics.
RESPiRatoRy-RELatEd diSoRdERS – health Care use & Policy Studies
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objeCtives: Pharmaceutical spending in Mexico represents approximately 25% of 
total health expenditures, with this number expected to grow by 14% from 2009-
2014. 90% of Mexico’s population receives health care from the public health system 
or Popular Health Insurance (PHI). A private insurance market has begun to take root. 
This study looks at how the increase in price controls and guidelines may impact 
access to newly approved Community Acquired Pneumonia (CAP) drugs. Methods: 
An array of published data such as pricing process, current policies, sector-specific 
research articles contributed towards a framework to understand the key factors 
affecting access to CAPs drugs, were gathered. The data then informed a telephone 
survey of national and regional health care stakeholders (N= 6). Results: Findings 
show that in Mexico: 1) New pressures through price negotiations are occurring 
due to economic challenges facing PHI; 2) Private purchasing of pharmaceutical 
products represents 56% of sold units worth 79% of total spend versus public pur-
chase representing 44% of sold units and 21% of total spend; 3) Formularies used by 
public coverage schemes require newly approved drugs for CAP to achieve marketing 
authorization, meet safety requirements and be cost effective versus comparator 
agents; and 4) International reference price serves as a benchmark for establish-
ing a price threshold. ConClusions: Drugs used to treat CAP are compared to 
comparator agents based on cost effectiveness. This will determine placement in 
the public formulary. The private pharmaceutical market may use data from the 
public formulary system when making a determination on price. Existing clinical 
guidelines in the public sector are non-binding, leaving the final decision on use 
to physicians. However, patient access to drugs for CAP may be impacted based on 
price negotiations and cost effectiveness analysis.
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objeCtives: To assess the knowledge, perception and practices with respect 
to antibiotic usage amongst the Indian population with an aim to sensitize the 
survey participants about the consequences of misuse of antibiotics. Methods: 
A questionnaire was designed around the use, misuse and consequences of anti-
biotic resistance based on latest National Policy for Antimicrobial Resistance of 
India. The survey was conducted using social media sites like facebook, twitter 
etc. The responses collected were classified as geographical locations, gender, 
age and occupation. Survey is designed in such a way that all the prevailing 
practices and views of the general public with respect to antibiotic usage are 
covered. Results: The prescription for antibiotic was 25% for common cold. 
Empirical antibiotic prescription was reported for 61% of the respondents. 14% 
preferred for a diagnostic test for guiding antibiotic prescription by doctors. 50% 
of the respondents preferred to purchase antibiotics directly from the chemist 
shops without the prescription of a doctor. Almost half of the respondents were 
not aware about the antibiotic resistance development due to environmental con-
tamination. 35% of the respondents affirmed to stopping the antibiotic regimen 
as soon as their symptoms subsided. ConClusions: The antibiotic resistance 
is a global phenomenon requiring the immediate reforms to curb as the danger 
of multi-drug resistant bacteria is a ticking time bomb. Our results have clearly 
indicated the misuse of antibiotics by public and practitioners which needs to 
be monitored and corrected immediately to prevent the catastrophe of epidem-
ics by MDR bacteria as the new antibiotics are not invented and old drugs are 
becoming ineffective.
responsible for an enormous burden of disease in the region. This evidence-based, 
internally and externally valid HEM showed to be an adequate tool for the assess-
ment of the effects of smoking and could be a useful policy-making tool to estimate 
the cost-effectiveness of tobacco control interventions.
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objetivos: Comparar os custos do tratamento de crianças hospitalizadas por pneu-
monia bacteriana adquirida na comunidade, considerando diferentes metodolo-
gias de custeio. Métodos: Estudo prospectivo realizado em Goiânia, Goiás/Brasil. 
Crianças com 28 dias a 35 meses internadas em 2 hospitais foram avaliadas. Três 
metodologias de custeio foram consideradas na perspectiva do Sistema Único de 
Saúde: (i) bottom-up/micro-costing através da revisão de prontuários; (ii) top-down/
micro-costing através de diretriz terapêutica; e (iii) top-down/gross-costing através 
de ressarcimento pago pelo SUS. Casos foram pacientes internados com suspeita 
clínica de pneumonia, receberam antibioticoterapia durante a internação e não 
tiveram diagnóstico final de pneumonia viral. Casos graves foram aqueles interna-
dos em enfermaria enquanto os internados em unidade de terapia intensiva foram 
considerados muito graves. Foram considerados custos diretos (medicamentos, 
honorários médicos e de fisioterapia respiratória, exames e diárias hospitalares 
em UTI e enfermaria) e não-médicos (diárias de acompanhantes). Os custos foram 
estimados em dólares americanos (USD) e reais (R$) considerando a taxa de câmbio 
oficial (1 USD = R$ 1,875) em dezembro de 2011. O teste de Friedman foi utilizado 
para comparar os resultados. ResultAdos: Foram analisados 59 casos (52 graves 
e 7 muito graves). Os custos de casos graves foram R$ 781 (USD 416) por bottom-up/
micro-costing, R$ 641 (USD 342) por top-down/micro-costing e R$ 597 (USD 318) por top-
down/gross-costing (p= 0,015). Para os casos muito graves, os custos foram R$ 3.539 
(USD 1.887) por bottom-up/micro-costing, R$ 3.369 (USD 1.796) por top-down/micro-
costing e R$ 3.175 (USD 1.693) por top-down/gross-costing (p= 0,018). Para ambos os 
grupos, houve diferença significativa apenas entre bottom-up/microcosting e top-down/
gross-costing. ConClusões: Nossos resultados sugerem a estimativa de custos por 
top-down/micro-costing através de diretriz terapêutica pode ser uma alternativa que 
se aproxima à estimativa considerando o bottom-up/microcosting através de revisão 
de prontuários, considerado o padrão ouro para estimativa de custos de doença.
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objeCtives: To assess the effectiveness and costs of the Smoking Cessation Program 
(SCP) in the Public Unified Health System (SUS) and to estimate the cost for its full 
implementation in the city of Goiânia, Brazil. Methods: The SCP intervention targets 
group of smokers, and includes medical visits, cognitive-behavioral group therapy, 
and medication use, lasting six months. Costs for SCP intervention and manage-
ment were estimated. The SCP full implementation was defined as the program’s 
expansion to meet the demand of all smokers motivated to quit smoking in the city 
of Goiânia. Direct medical and non-medical direct costs were considered, including 
staff, medications, consumables, general expenses, transportation, travel, events and 
capital costs. Microcosting and activity-based costing methods were used. Cost for 
the federal, state and municipal levels were estimated. The SUS perspective was 
considered. Two-way sensitivity analysis was conducted. Data sources included a 
convenience sample of primary health facilities, municipal and state health depart-
ments, and the Ministry of Health. Costs were estimated in Reais (R$) and U.S. Dollars 
(USD), considering the exchange rate of December/2010, which was 1.67. Quitting rates 
were estimated as the percentage of patients who reported not smoking at the end 
of the intervention. Costs of the SCP are presented as total cost of the intervention; 
costs stratified by component and level of funding source; cost per patient; and cost 
per quitter. Results: The average quitting rate was 37.2%. The cost of SCP in Goiânia 
was R$428,580 (US$257,220), of which 23% were program management costs. Cost 
per patient was R$534 (US$320) and cost per quitter was R$1,433 (US$860). The SCP’s 
full implementation reaching the estimated 37,455 smokers in Goiânia motivated to 
quit would cost R$21.5 million (US$13). ConClusions: The SCP is highly effective. 
Additional efficiency could be gained by expanding patient’s access to the program.
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